drugset / Trial / NCT00645372

A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

NCT00645372

Phase 3 Completed 242 enrolled Viatris Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients

Timeline

Start
2004-07
Primary completion
Completion
2005-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Risperidone Other / unclassified 1 mg Oral
Comparator Risperidone Other / unclassified 2 mg Oral
Comparator Risperidone Other / unclassified 3 mg Oral
Subject Ziprasidone Small molecule 40 mg Oral
Subject Ziprasidone Small molecule 60 mg Oral
Subject Ziprasidone Small molecule 80 mg Oral

Indications